PRAX at a glance
Praxis Precision Medicines, Inc. (PRAX, SEC CIK 1689548) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Praxis Precision Medicines, Inc. (PRAX) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $303.3 million. Diluted EPS was -$13.48.
- As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Praxis Precision Medicines, Inc. (PRAX) shares worth $3.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by DeSimone Jill on June 24, 2026 of 683 shares at $306.77 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- −100.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 32 funds
- $3.2B · +0 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 7.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Precision neuroscience biopharma developing therapies for CNS disorders from genetic epilepsies via two platforms, Cerebrum™ (small molecules) and Solidus™ (antisense oligonucleotides)
- New emphasis on clinical development with four clinical-stage candidates; submitted NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A-DEE, SCN8A-DEE)
- Strategic shift to expanded clinical and commercial preparations for NDA-stage assets and ongoing Phase 3 programs (POWER1, POWER2 for vormatrigine) targeting broader epilepsy and CNS disorders
- Quantitative highlight: ~7 million US essential tremor patients, 54% median seizure reduction in RADIANT vormatrigine Phase 2, 53% placebo-adjusted seizure reduction with relutrigine in EMBOLD Phase 2
- Noteworthy: FDA granted Breakthrough Therapy Designation for ulixacaltamide and relutrigine; first commercial collaboration in Greater China for ulixacaltamide launched
Risk Factors
- Regulatory risk: ongoing FDA review of NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A and SCN8A DEEs) with uncertain approval timing or outcome
- Macroeconomic exposure: cash runway extends into 2028 but risks of faster cash burn due to increased R&D, clinical trials, or unexpected costs
- Supply chain vulnerability: potential delays or failure in manufacturing scale-up or third-party clinical/commercial supply arrangements
- Competitive risk: failure to address competing technologies or market acceptance risks amid evolving neurology drug landscape
- Financial risk: accumulated deficit $1.1 billion with net losses $303.3 million in 2025 and $182.8 million in 2024, requiring additional capital raising that could dilute shareholders
Management Discussion & Analysis
- No revenues reported; focused on R&D and pre-commercial activities with expected substantial operating expense increases
- Operating losses expected to grow due to advancing clinical trials, commercialization prep, and infrastructure buildout; no margin % disclosed
- No segment performance breakdown; primary activities in Cerebrum™ and Solidus™ platforms with collaborative IP licensing arrangements
- Cash, cash equivalents, and marketable securities plus January 2026 follow-on offering proceeds expected to fund operations into 2028; lease and licensing commitments total $1.6M plus milestone payments (e.g., $3.0M to RogCon, $6.9M to Ionis)
- Risks: high R&D costs, uncertainty of approval and commercialization, potential need for additional capital with dilution risk, market volatility affecting funding access
AI summary of the PRAX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Carried-forward risks include clinical development, regulatory approval, commercialization, financing, competition, and intellectual property challenges
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales since inception
- Net loss $94.2M vs $73.9M YoY, operating loss $106.9M vs $78.4M
- R&D $64.2M vs $65.8M, Cerebrum™ highest at $40.4M, Solidus™ $2.8M
- Cash, equivalents and marketable securities $1.3B, operating cash use $245.4M for nine months
- Ulixacaltamide PDUFA January 29, 2027, relutrigine updated to December 27, 2026, POWER1 endpoint failure headwind
AI summary of the PRAX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Investor Day presentation disclosed on November 12, 2026, covering Praxis Precision Medicines’ investor-focused updates
- Presentation available at investors.praxismedicines.com and furnished as Exhibit 99.1
Item 8.01: Other Events
- Ulixacaltamide targets about 2 million treatment-seeking U.S. ET patients within an estimated 9 million prevalence population
- Essential3 endpoint sensitivity analyses matched the primary result, supporting the NDA’s evidentiary consistency
Item EX-99.1: Item EX-99.1
- Investor Day outlines two planned launches: relutrigine on December 27, 2026 and ulixacaltamide on January 29, 2027
- Ulixacaltamide PDUFA date January 29, 2027, creating a near-term regulatory catalyst in essential tremor
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Press release containing the results furnished as Exhibit 99.1
Item EX-99.1: Item EX-99.1
- FDA decisions pending for ulixacaltamide on January 29, 2027 and relutrigine on December 27, 2026, key commercialization catalysts
- Cash and investments $1.3B as of September 30, 2026, supporting operations into 2028 and reducing near-term financing risk
Item 2.02: Results of Operations and Financial Condition
- Fiscal results announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing detailed financial results and management commentary
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation for investor and analyst meetings as of August 6, 2026
- Presentation available on Praxis’s investor website and furnished as Exhibit 99.2
Item EX-99.2: Item EX-99.2
- Four late-stage CNS assets, including two PDUFA dates: relutrigine December 27, 2026 and ulixacaltamide January 2027
- Portfolio peak-sales potential above $20B, led by ulixacaltamide above $10B and relutrigine above $5B
Item EX-99.1: Item EX-99.1
- Q2 net loss $83.7M, or $2.87 per share, versus $71.1M and $3.31 in Q2 2025
- Cash and investments $1.4B, up from $926.1M, extending operations into 2028
AI summaries of PRAX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PRAX
Don't miss the next PRAX filing
- Alerts as it files. A push when PRAX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PRAX, by share count.
- Ask anything. An AI agent that reads every PRAX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Nemiroff Alex | A | Nov 13, 2026 | 49 | $278.91 |
| Sniecinski Megan | A | Nov 13, 2026 | 21 | $278.91 |
| Mastrocola Lauren | A | Nov 13, 2026 | 72 | $278.91 |
| Kelly Timothy Edwin | A | Nov 13, 2026 | 3 | $278.91 |
| Souza Marcio | G | Jul 8, 2026 | 2,600 | - |
| Souza Marcio | G | Jul 8, 2026 | 20,521 | - |
| DeSimone Jill | Sell | Jun 24, 2026 | 683 | $306.77 |
| DeSimone Jill | Sell | Jun 24, 2026 | 320 | $305.31 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $2.4M | $8.6M | $0 |
| Operating Income | - | -$200.2M | -$326.2M |
| Net Income | -$123.3M | -$182.8M | -$303.3M |
| Op. Margin | - | -2340.3% | - |
| Net Margin | -5037.9% | -2137.5% | - |
| Balance Sheet | |||
| Total Assets | - | $483.1M | $937.9M |
| Equity | - | $445.4M | $878.1M |
| ROE | - | -41.0% | -34.5% |
| Per Share | |||
| EPS | $-18.69 | $-10.21 | $-13.48 |
| Cash Flow | |||
| Operating CF | -$111.1M | -$131.8M | -$249.1M |
| CapEx | - | $0 | $56K |
Source: XBRL data in Praxis Precision Medicines, Inc. (PRAX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PRAX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 32 | $3.15B |
| Q2 2026 | 32 | $4.24B |
| Q1 2026 | 30 | $3.54B |
| Q4 2025 | 29 | $2.81B |
| Q3 2025 | 23 | $397.9M |
| Q2 2025 | 21 | $321.3M |
| Q1 2025 | 20 | $172.1M |
| Q4 2024 | 18 | $239.4M |
- Bank of America Corp+343.7K (+63%)
- Franklin Resources+255.2K (+78%)
- Invesco Ltd+44.7K (+8%)
- State Street Corp+18.0K (+2%)
- Citigroup+13.8K (+59%)
- BlackRock−59.8K (-3%)
- Goldman Sachs Group−56.2K (-10%)
- T. Rowe Price Group−54.6K (-6%)
- Vanguard Portfolio Management LLC−30.5K (-2%)
- Morgan Stanley−20.1K (-2%)
- Truist Financial+1.5K
- FMR LLC (Fidelity)−2.32M
Source: 13F-HR filings on SEC EDGAR (aggregated from 205 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PRAX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 8, 2026 | - | - | - |
| 8-K | Jul 7, 2026 | - | Analysis | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 1, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PRAX SEC filings: frequently asked questions
Which institutions hold PRAX stock?
As of September 30, 2026, the largest Praxis Precision Medicines, Inc. (PRAX) holders among the 13F filers tracked by SignalX were BlackRock ($650.3 million), Vanguard Portfolio Management LLC ($380.0 million), Vanguard Capital Management LLC ($357.9 million), State Street Corp ($304.1 million), Bank of America Corp ($259.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PRAX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Praxis Precision Medicines, Inc. (PRAX) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $303.3 million. Diluted EPS was -$13.48. The figures come from the XBRL data in the 10-K.
What are the main risks in PRAX's latest 10-K?
In the 10-K filed February 19, 2026, Praxis Precision Medicines, Inc. (PRAX) flagged: Regulatory risk: ongoing FDA review of NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A and SCN8A DEEs) with uncertain approval timing or outcome. Macroeconomic exposure: cash runway extends into 2028 but risks of faster cash burn due to increased R&D, clinical trials, or unexpected costs. (AI summary of the Risk Factors section.)
What did PRAX report in its latest 8-K?
Praxis Precision Medicines, Inc. (PRAX) filed an 8-K on November 12, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Investor Day presentation disclosed on November 12, 2026, covering Praxis Precision Medicines’ investor-focused updates.
What are the latest PRAX SEC filings?
Praxis Precision Medicines, Inc. (PRAX) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 18, 2026.
What is PRAX's SEC CIK number?
Praxis Precision Medicines, Inc. (PRAX)'s SEC Central Index Key (CIK) is 1689548. EDGAR lists every PRAX filing under that number.
Ask anything about PRAX
The research agent reads PRAX's filings, financials, insider trades and 13F holders, then answers with sources.